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We read with interest the article “Case 
Report: High Prenatal Bisphenol A Exposure 
and Infant Neonatal Neurobehavior” by 
Sathyanarayana et al. (2011). In their arti‑
cle, the authors proposed a potential asso‑
ciation between a single, exceedingly high 
concentration of urinary bisphenol A (BPA) 
measured at the beginning of the third tri‑
mester of pregnancy in a single case mother 
and a single abnormal neuro  logical assess‑
ment conducted 4 months later in a single 
and apparently otherwise healthy infant at 
approximately 1 month of age. We have 
several comments and concerns about this 
article and its conclusions. 
First, the urinary BPA results for the 
mother at the 16‑week gestation test and just 
after birth were not abnormally elevated; the 
only elevated concentration was at the 26‑week 
gestation test. Sathyanarayana et al. (2011) 
reported that the elevated BPA level was the 
highest of any reported in the peer‑reviewed 
literature and that the bio  analytical laboratory 
repeated the analysis to confirm the result. The 
actual values detected in the repeated analysis 
were not provided in the article, precluding 
readers from independently concluding that 
the result was likely not spurious.
Second, Sathyanarayana et al. (2011) 
stated that at 26 weeks of gestation the major‑
ity of the BPA in the urine sample was conju‑
gated, indicating that it had been metabolized 
and thus did not reflect external contamina‑
tion. It should be noted that glucuronidated 
BPA is not biologically active. The authors 
did not propose a potential mechanism by 
which conjugated BPA may exert neurologi‑
cal effects. 
Third, although the neuro  logical assess‑
ment conducted on the infant at approxi‑
mately 1 month of age was considered 
abnormal, neuro  logical assessments at 14 hr 
after birth and annually at 1–5 years of age 
were within normal limits, suggesting a 
spurious event. Also, it is unclear whether 
“normal limits” refers to results at 1–5 years 
of age for children in the Health Outcomes 
and Measures of the Environment (HOME) 
Study from which this case study was gener‑
ated (and with which the 1‑month assess‑
ment results were compared) or to some 
other data set. If it is the latter, the authors 
would appear to have compared the child’s 
assessment results with two different data sets 
and drawn different conclusions from them 
without indicating whether (and how) the 
data sets differ.
The preceding items and other state‑
ments in the article raise doubt about the 
plausibility of a link between the single 
high urinary BPA measure  ment and the 
single abnormal neurological assessment. 
For example, Sathyanarayana et al. (2011) 
did not know how long the child exhibited 
symptoms after the abnormal assessment was 
conducted. The authors did not indicate that 
any follow‑up tests were performed to detect 
ailments that may have been the cause of 
the abnormal findings; they stated only that 
there was “no obvious etiology.” The authors 
reported that they referred the mother to her 
primary physician, but the only information 
they provided regarding the results of the 
follow‑up or when it occurred was that 
[The] abnormal findings were not noted by any 
other medical assessments performed by health 
care providers, including the primary medical 
doctor for the infant. (Sathyanarayana et al. 2011)
Most strikingly, the authors stated that 
Other infants within the HOME Study had 
abnormal neurologic examinations, but some of 
these mothers did not have elevated prenatal uri‑
nary BPA concentrations. These cases may have 
resulted from other etiologies of abnormal neuro‑
behavior that have not yet been explored. 
We argue that the case infant also may have 
had such etiologies that were not explored. 
Thus, it is unclear to us why Sathyanarayana 
et al. (2011) chose to conduct and report a 
case study on this single infant, other than 
the fact that the mother had an unusually 
high urinary BPA concentration at a single 
time point.
In conclusion, we feel that it is highly 
likely that the elevated third‑trimester urinary 
BPA concentration had absolutely nothing 
to do with the single abnormal neuro  logi  cal 
assessment in the case infant. We do not 
consider this study to be “hypothesis gener‑
ating” but rather to simply fan the flames of 
a topic that has received substantial media 
attention, much of which is overblown and 
not supported scientifically. We recom‑
mend that the authors consider reviewing 
the Bradford Hill criteria for establishing 
causality before suggesting and publishing 
possible cause‑and‑effect relationships based 
on a single case study.
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In their letter, Haighton et al. recommend 
that we review Bradford Hill guidelines for 
establishing causality. As noted in our article 
(Sathyanarayana et al. 2011), we did not try 
to establish cause and effect with this single 
case study and cautioned against doing so. 
In medical research, new syndromes or toxi‑
cants have often been identified by the report 
of unusual cases or exposures, even though it 
is not always apparent with the initial case 
report. Thus, we believe that it is important 
to highlight this and other unusual cases to 
identify potential causative agents of neuro‑
behavioral abnormalities in childhood. This 
case study does not stand in isolation; there is 
a growing body of animal and human litera‑
ture documenting the neuro  developmental 
impacts of bisphenol A (BPA) exposure 
(Braun et al. 2009; National Toxicology 
Program, Center for the Evaluation of Risks 
to Human Reproduction 2008; Yolton et al. 
2011). 
Haighton et al. state that glucuroni‑
dated BPA does not appear to be biologi‑
cally active in mammalian systems; however, 
glucuronidated BPA can be deconjugated 
by the placenta or transferred across the 
placenta, where it can be deconjugated by 
other fetal tissues (Ginsberg and Rice 2009; 
Nishikawa et al. 2010). Therefore, a devel‑
oping fetus can be exposed to a biologically 
active substance. Also, more recent litera‑
ture has noted that BPA may be metabolized 
into other biologically active agents through 
oxidative cleavage to create the estrogeni‑
cally active metabolite 4‑methyl‑2,4‑bis(4‑
hydroxy  phenyl)pent‑1‑ene (MBP), which is 
reported to be 500 times more potent than 
BPA in vivo (Okuda et al. 2010).
The authors were unclear about 
how “normal limits” for neuro  behavioral 
assessment are defined. In our study 
(Sathyanarayana et al. 2011), we adminis‑
tered a wide range of standardized tests 
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